Sanofi taps Alloy Therapeutics for CNS antisense drug development

Sanofi and Alloy Therapeutics have partnered to develop a new antisense oligonucleotide (ASO) therapy for a CNS condition. Sanofi will pay Alloy up to $27.5m upfront and $400m+ in milestone payments.